These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Mitomycin-C in hyperopic photorefractive keratectomy.
    Author: Leccisotti A.
    Journal: J Cataract Refract Surg; 2009 Apr; 35(4):682-7. PubMed ID: 19304089.
    Abstract:
    PURPOSE: To evaluate the effects of topical mitomycin-C (MMC) after hyperopic photorefractive keratectomy (PRK). SETTING: Private practice, Siena, Italy. METHODS: In this prospective study, a sponge with 0.2 mg/mL MMC or balanced salt solution (controls) was placed on the stroma for 45 seconds after PRK performed using a Technolas 217z laser. After epithelialization, fluorometholone 0.1% eyedrops were used for 4 months in both groups. RESULTS: The MMC group comprised 88 eyes (mean spherical equivalent [SE] +3.51 diopters [D] +/- 1.04) and the control group, 91 eyes (mean SE +3.50 +/- 1.03 D). At 18 months, the mean SE was -0.10 +/- 0.37 D and 0.22 +/- 0.70 D, respectively, and the mean defocus equivalent, 0.34 +/- 0.32 D and 0.69 +/- 0.74 D, respectively (both P<.05). The mean best spectacle-corrected visual acuity (BSCVA) was 0.06 +/- 0.08 logMAR in the MMC group and 0.08 +/- 0.10 logMAR in the control group; 2 eyes and 11 eyes, respectively, lost more than 0.1 logMAR of BSCVA. The mean uncorrected visual acuity (UCVA) was 0.13 +/- 0.11 logMAR in the MMC group and 0.21 +/- 0.20 logMAR in the control group (P<.05). The UCVA was better than 20/40 in 94% of eyes and 80% of eyes, respectively. The efficacy index was 0.87 and 0.67, respectively. Haze at 18 months was 0.05 +/- 0.11 in the MMC group and 0.23 +/- 0.46 in the control group (P<.05). No endothelial damage was observed in either group. CONCLUSION: Mitomycin-C prevented haze formation and improved predictability and efficacy. No adverse effects occurred.
    [Abstract] [Full Text] [Related] [New Search]